# Baxter International Inc: financial statements, quarterly

BAX · NYSE · CIK 10456 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bax.md) · [Financials](/companies/bax/financials.md) · [Filings](/companies/bax/filings.md) · [Insiders](/companies/bax/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bax/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,729](/filings/0001628280-25-007201.md) | [2,490](/filings/0001628280-25-022727.md) | [2,694](/filings/0001628280-25-037877.md) | [2,699](/filings/0001628280-25-048897.md) | [2,753](/filings/0001628280-25-007201.md) | [2,625](/filings/0001628280-26-028962.md) | [2,810](/filings/0001628280-26-051118.md) | [2,835](/filings/0001628280-26-068278.md) | [2,974 d](/filings/0001628280-26-007733.md) | [2,701](/filings/0001628280-26-028962.md) | [2,960](/filings/0001628280-26-051118.md) | [2,976](/filings/0001628280-26-068278.md) |
| Cost of revenue | $m | [1,626 d](/filings/0001628280-26-007733.md) | [1,529](/filings/0001628280-25-022727.md) | [1,663](/filings/0001628280-25-037877.md) | [1,666](/filings/0001628280-25-048897.md) | [1,794 d](/filings/0001628280-26-007733.md) | [1,764](/filings/0001628280-26-028962.md) | [1,819](/filings/0001628280-26-051118.md) | [1,885](/filings/0001628280-26-068278.md) | [2,397 d](/filings/0001628280-26-007733.md) | [1,810](/filings/0001628280-26-028962.md) | [1,928](/filings/0001628280-26-051118.md) | [1,982](/filings/0001628280-26-068278.md) |
| Gross profit | $m | [1,100](/filings/0001628280-25-007201.md) | [961](/filings/0001628280-25-022727.md) | [1,031](/filings/0001628280-25-037877.md) | [1,033](/filings/0001628280-25-048897.md) | [959](/filings/0001628280-25-007201.md) | [861](/filings/0001628280-26-028962.md) | [991](/filings/0001628280-26-051118.md) | [950](/filings/0001628280-26-068278.md) | [577 d](/filings/0001628280-26-007733.md) | [891](/filings/0001628280-26-028962.md) | [1,032](/filings/0001628280-26-051118.md) | [994](/filings/0001628280-26-068278.md) |
| Research and development | $m | [127 d](/filings/0001628280-26-007733.md) | [120](/filings/0001628280-25-022727.md) | [130](/filings/0001628280-25-037877.md) | [129](/filings/0001628280-25-048897.md) | [211 d](/filings/0001628280-26-007733.md) | [140](/filings/0001628280-26-028962.md) | [134](/filings/0001628280-26-051118.md) | [118](/filings/0001628280-26-068278.md) | [126 d](/filings/0001628280-26-007733.md) | [139](/filings/0001628280-26-028962.md) | [129](/filings/0001628280-26-051118.md) | [125](/filings/0001628280-26-068278.md) |
| Selling, general and administrative | $m | [683 d](/filings/0001628280-26-007733.md) | [729](/filings/0001628280-25-022727.md) | [723](/filings/0001628280-25-037877.md) | [754](/filings/0001628280-25-048897.md) | [761 d](/filings/0001628280-26-007733.md) | [703](/filings/0001628280-26-028962.md) | [718](/filings/0001628280-26-051118.md) | [708](/filings/0001628280-26-068278.md) | [761 d](/filings/0001628280-26-007733.md) | [728](/filings/0001628280-26-028962.md) | [735](/filings/0001628280-26-051118.md) | [730](/filings/0001628280-26-068278.md) |
| Operating income | $m | [304 d](/filings/0001628280-26-007733.md) | [115](/filings/0001628280-25-022727.md) | [179](/filings/0001628280-25-037877.md) | [155](/filings/0001628280-25-048897.md) | [(435) d](/filings/0001628280-26-007733.md) | [58.0](/filings/0001628280-26-028962.md) | [191](/filings/0001628280-26-051118.md) | [172](/filings/0001628280-26-068278.md) | [(729) d](/filings/0001628280-26-007733.md) | [66.0](/filings/0001628280-26-028962.md) | [217](/filings/0001628280-26-051118.md) | [225](/filings/0001628280-26-068278.md) |
| Interest expense | $m | [113 d](/filings/0001628280-26-007733.md) | [103](/filings/0001628280-24-019786.md) | [104](/filings/0001628280-24-034965.md) | [(14.0)](/filings/0001628280-25-048897.md) | [465 d](/filings/0001628280-26-007733.md) | [(17.0)](/filings/0001628280-26-028962.md) | [(14.0)](/filings/0001628280-26-051118.md) | [(10.0)](/filings/0001628280-26-068278.md) | [331 d](/filings/0001628280-26-007733.md) | [(12.0)](/filings/0001628280-26-028962.md) | [(13.0)](/filings/0001628280-26-051118.md) | [(13.0)](/filings/0001628280-26-068278.md) |
| Income tax | $m | [2.0 d](/filings/0001628280-26-007733.md) | [40.0](/filings/0001628280-25-022727.md) | [22.0](/filings/0001628280-25-037877.md) | [8.0](/filings/0001628280-25-048897.md) | [(33.0) d](/filings/0001628280-26-007733.md) | [(67.0)](/filings/0001628280-26-028962.md) | [11.0](/filings/0001628280-26-051118.md) | [172](/filings/0001628280-26-068278.md) | [279 d](/filings/0001628280-26-007733.md) | [11.0](/filings/0001628280-26-028962.md) | [23.0](/filings/0001628280-26-051118.md) | [119](/filings/0001628280-26-068278.md) |
| Net income | $m | [245](/filings/0001628280-25-007201.md) | [37.0](/filings/0001628280-25-022727.md) | [(314)](/filings/0001628280-25-037877.md) | [140](/filings/0001628280-25-048897.md) | [(512)](/filings/0001628280-25-007201.md) | [126](/filings/0001628280-26-028962.md) | [91.0](/filings/0001628280-26-051118.md) | [(46.0)](/filings/0001628280-26-068278.md) | [(1,128) d](/filings/0001628280-26-007733.md) | [(15.0)](/filings/0001628280-26-028962.md) | [126](/filings/0001628280-26-051118.md) | [294](/filings/0001628280-26-068278.md) |
| Diluted EPS | $ per share | [0.48](/filings/0001628280-25-007201.md) | [0.07](/filings/0001628280-25-022727.md) | [(0.61)](/filings/0001628280-25-037877.md) | [0.27](/filings/0001628280-25-048897.md) | [(1.00)](/filings/0001628280-25-007201.md) | [0.25](/filings/0001628280-26-028962.md) | [0.18](/filings/0001628280-26-051118.md) | [(0.09)](/filings/0001628280-26-068278.md) | not reported | [(0.03)](/filings/0001628280-26-028962.md) | [0.24](/filings/0001628280-26-051118.md) | [0.57](/filings/0001628280-26-068278.md) |
| Basic EPS | $ per share | [0.48](/filings/0001628280-25-007201.md) | [0.07](/filings/0001628280-25-022727.md) | [(0.62)](/filings/0001628280-25-037877.md) | [0.27](/filings/0001628280-25-048897.md) | [(1.00)](/filings/0001628280-25-007201.md) | [0.25](/filings/0001628280-26-028962.md) | [0.18](/filings/0001628280-26-051118.md) | [(0.09)](/filings/0001628280-26-068278.md) | not reported | [(0.03)](/filings/0001628280-26-028962.md) | [0.24](/filings/0001628280-26-051118.md) | [0.57](/filings/0001628280-26-068278.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [3.1](/filings/0001628280-26-007733.md) | [2.8](/filings/0001628280-25-022727.md) | [1.6](/filings/0001628280-25-037877.md) | [1.4](/filings/0001628280-25-048897.md) | [1.8](/filings/0001628280-26-007733.md) | [2.3](/filings/0001628280-26-028962.md) | [1.7](/filings/0001628280-26-051118.md) | [1.7](/filings/0001628280-26-068278.md) | [2.0](/filings/0001628280-26-068278.md) | [2.0](/filings/0001628280-26-028962.md) | [2.2](/filings/0001628280-26-051118.md) | [2.0](/filings/0001628280-26-068278.md) |
| Current assets | $bn | [9.6](/filings/0001628280-25-007201.md) | [9.4](/filings/0001628280-24-019786.md) | [8.6](/filings/0001628280-24-034965.md) | [8.9](/filings/0001628280-24-047221.md) | [8.9](/filings/0001628280-26-007733.md) | [7.0](/filings/0001628280-25-022727.md) | [6.7](/filings/0001628280-25-037877.md) | [6.9](/filings/0001628280-25-048897.md) | [6.9](/filings/0001628280-26-068278.md) | [6.8](/filings/0001628280-26-028962.md) | [7.0](/filings/0001628280-26-051118.md) | [6.8](/filings/0001628280-26-068278.md) |
| Total assets | $bn | [28.3](/filings/0001628280-25-007201.md) | [27.8](/filings/0001628280-24-019786.md) | [26.3](/filings/0001628280-24-034965.md) | [26.7](/filings/0001628280-24-047221.md) | [25.8](/filings/0001628280-26-007733.md) | [21.3](/filings/0001628280-25-022727.md) | [21.0](/filings/0001628280-25-037877.md) | [21.1](/filings/0001628280-25-048897.md) | [20.1](/filings/0001628280-26-068278.md) | [19.8](/filings/0001628280-26-028962.md) | [19.8](/filings/0001628280-26-051118.md) | [19.4](/filings/0001628280-26-068278.md) |
| Current liabilities | $bn | [6.5](/filings/0001628280-25-007201.md) | [6.4](/filings/0001628280-24-019786.md) | [6.1](/filings/0001628280-24-034965.md) | [6.2](/filings/0001628280-24-047221.md) | [6.5](/filings/0001628280-26-007733.md) | [3.5](/filings/0001628280-25-022727.md) | [2.9](/filings/0001628280-25-037877.md) | [3.8](/filings/0001628280-25-048897.md) | [3.0](/filings/0001628280-26-068278.md) | [3.7](/filings/0001628280-26-028962.md) | [3.6](/filings/0001628280-26-051118.md) | [3.8](/filings/0001628280-26-068278.md) |
| Total liabilities | $bn | [19.8](/filings/0001628280-25-007201.md) | [19.6](/filings/0001628280-24-019786.md) | [18.6](/filings/0001628280-24-034965.md) | [18.7](/filings/0001628280-24-047221.md) | [18.8](/filings/0001628280-26-007733.md) | [14.3](/filings/0001628280-25-022727.md) | [13.8](/filings/0001628280-25-037877.md) | [13.9](/filings/0001628280-25-048897.md) | [14.0](/filings/0001628280-26-068278.md) | [13.8](/filings/0001628280-26-028962.md) | [13.6](/filings/0001628280-26-051118.md) | [12.9](/filings/0001628280-26-068278.md) |
| Long-term debt | $bn | [13.9](/filings/0001628280-24-003932.md) | not reported | not reported | not reported | [13.2](/filings/0001628280-25-007201.md) | not reported | not reported | not reported | [9.4](/filings/0001628280-26-007733.md) | not reported | not reported | not reported |
| Short-term borrowings | $bn | [0.0](/filings/0001628280-25-007201.md) | not reported | not reported | not reported | [2.1](/filings/0001628280-26-007733.md) | [0.0](/filings/0001628280-25-022727.md) | [0.0](/filings/0001628280-25-037877.md) | [0.0](/filings/0001628280-25-048897.md) | [0.0](/filings/0001628280-26-068278.md) | [0.0](/filings/0001628280-26-028962.md) | [0.0](/filings/0001628280-26-051118.md) | [0.0](/filings/0001628280-26-068278.md) |
| Shareholders' equity | $bn | [8.4](/filings/0001628280-25-007201.md) | [8.2](/filings/0001628280-24-019786.md) | [7.6](/filings/0001628280-24-034965.md) | [7.9](/filings/0001628280-24-047221.md) | [7.0](/filings/0001628280-26-007733.md) | [7.1](/filings/0001628280-25-022727.md) | [7.3](/filings/0001628280-25-037877.md) | [7.2](/filings/0001628280-25-048897.md) | [6.1](/filings/0001628280-26-068278.md) | [6.0](/filings/0001628280-26-028962.md) | [6.2](/filings/0001628280-26-051118.md) | [6.5](/filings/0001628280-26-068278.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [531 d](/filings/0001628280-26-007733.md) | [163](/filings/0001628280-25-022727.md) | [115 d](/filings/0001628280-25-037877.md) | [253 d](/filings/0001628280-25-048897.md) | [488 d](/filings/0001628280-26-007733.md) | [(193)](/filings/0001628280-26-028962.md) | [217 d](/filings/0001628280-26-051118.md) | [237 d](/filings/0001628280-26-068278.md) | [584 d](/filings/0001628280-26-007733.md) | [213](/filings/0001628280-26-028962.md) | [285 d](/filings/0001628280-26-051118.md) | [558 d](/filings/0001628280-26-068278.md) |
| Capital expenditure | $m | [(70.0) d](/filings/0001628280-26-007733.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [147 d](/filings/0001628280-26-007733.md) | [147](/filings/0001628280-25-022727.md) | [148 d](/filings/0001628280-25-037877.md) | [148 d](/filings/0001628280-25-048897.md) | [147 d](/filings/0001628280-26-007733.md) | [87.0](/filings/0001628280-26-028962.md) | [87.0 d](/filings/0001628280-26-051118.md) | [87.0 d](/filings/0001628280-26-068278.md) | [87.0 d](/filings/0001628280-26-007733.md) | [5.0](/filings/0001628280-26-028962.md) | [5.0 d](/filings/0001628280-26-051118.md) | [5.0 d](/filings/0001628280-26-068278.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-25-007201.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [505](/filings/0001628280-24-019786.md) | [506](/filings/0001628280-24-034965.md) | [509](/filings/0001628280-24-047221.md) | [510](/filings/0001628280-25-022727.md) | [511](/filings/0001628280-25-037877.md) | [512](/filings/0001628280-25-048897.md) | [514](/filings/0001628280-26-028962.md) | [514](/filings/0001628280-26-051118.md) | [514](/filings/0001628280-26-068278.md) | [515](/filings/0001628280-26-028962.md) | [518](/filings/0001628280-26-051118.md) | [520](/filings/0001628280-26-068278.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 517,348,188 at 2026-10-22, from the cover of the [10-Q filed 2026-10-29](/filings/0001628280-26-068278.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:43 ET. No prices; not investment advice.